MedTrace Logo

T790M Mutation Positive 2nd Line STandard of cAre Registry

NCT02368990 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-07-08

No results posted yet for this study

Summary

The aim of the study is to collect real world information on patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who progressed after first line treatment with an approved Tyrosine-Kinase Inhibitor (TKI), who are known to be T790M positive and have been prescribed second line platinum-based chemotherapy (Pemetrexed + Cisplatin /Carboplatin).

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • AstraZeneca

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2018-06-30
Completion
2018-06-30

Countries

  • United States
  • China
  • France
  • Germany
  • Italy
  • Netherlands
  • Russia
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02368990 on ClinicalTrials.gov